Abstract
Population-based screening programs have reduced significantly cervical cancer burden in high-income countries over the past few decades. Low- and middle-income countries have failed to show a major impact on cervical cancer control, even in settings where cytology- or visual inspection-based screening activities are ongoing. Widespread use of HPV vaccine is the most promising strategy to avoid disease development. Nevertheless, a vaccine population-based approach is still limited to some settings, and the impact of mass vaccination is not expected for some time. In 2016 the American Society of Clinical Oncology issued a stratified guideline addressing global resources disparities. The goal of this chapter is to debate challenges from low- and middle-income countries to implement successful cervical cancer screening programs in order to reduce cancer burden. The feasibility for introduction of new technologies, like the HPV-DNA-based tests, will be analyzed according to the different scenarios. This intends to be a critical review addressing aspects of organization of screening programs in the view of global disparities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013 [cited 2016 Dec 9]. http://globocan.iarc.fr/Default.aspx
Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet Lond Engl. 2011;378(9801):1461–84.
World Bank. How does the World Bank classify countries? – World Bank Data Help Desk [Internet]. [cited 2017 Jun 24]. https://datahelpdesk.worldbank.org/knowledgebase/articles/378834-how-does-the-world-bank-classify-countries
American Society of Clinical Oncology. New cervical cancer guideline addresses global resource disparities [Internet]. ASCO. 2016 [cited 2017 Jun 24]. https://www.asco.org/about-asco/press-center/news-releases/new-cervical-cancer-guideline-addresses-global-resource
United Nations. Sustainable development goals: 17 goals to transform our world [Internet]. United Nations Sustainable Development. [cited 2017 Jun 24]. http://www.un.org/sustainabledevelopment/
Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45(15):2640–8.
Lăără E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet. 1987;1(8544):1247–9.
Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249–56.
Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008;26:L37–48.
Ponti A, et al. Cancer screening in the European Union: second report on implementation [Internet]. [cited 2017 Apr 24]. https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndreportimplementation_en.pdf
Walsh B, Silles M, O’Neill C. The importance of socio-economic variables in cancer screening participation: a comparison between population-based and opportunistic screening in the EU-15. Health Policy Amst Neth. 2011;101(3):269–76.
Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care. 2004;42(6):600–9.
do Vale DBAP, Morais SS, Pimenta AL, Zeferino LC. Assessment of the cervical cancer screening in the Family Health Strategy in Amparo, São Paulo State, Brazil. Cad Saude Publica. 2010;26(2):383–90.
Palència L, Espelt A, Rodríguez-Sanz M, Puigpinós R, Pons-Vigués M, Pasarín MI, et al. Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program. Int J Epidemiol. 2010;39(3):757–65.
Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer. 2000;86(3):440–7.
Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2005;89(Suppl 2):S4–12.
International Agency for Research on Cancer. IARC handbooks of cancer prevention: cervix cancer screening. Vol. 10. IARC; 2005.
Rozemeijer K, Naber SK, Penning C, Overbeek LIH, Looman CWN, de Kok IMCM, et al. Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ. 2017;356:j504.
Rozemeijer K, Penning C, Siebers AG, Naber SK, Matthijsse SM, van Ballegooijen M, et al. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Cancer Causes Control. 2016;27(1):15–25.
Sankaranarayanan R, Nessa A, Esmy PO, Dangou J-M. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):221–32.
WHO. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention [Internet]. WHO. [cited 2015 Aug 11]. http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.
Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–90.
Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.
Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.
Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and Papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24(3):576–85.
Zhao F-H, Lewkowitz AK, Chen F, Lin MJ, Hu S-Y, Zhang X, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012;104(3):178–88.
Gök M, van Kemenade FJ, Heideman DAM, Berkhof J, Rozendaal L, Spruyt JWM, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer. 2012;130(5):1128–35.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vale, D.B., Bragança, J.F., Zeferino, L.C. (2019). Cervical Cancer Screening in Low- and Middle-Income Countries. In: Farghaly, S. (eds) Uterine Cervical Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-02701-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-02701-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02700-1
Online ISBN: 978-3-030-02701-8
eBook Packages: MedicineMedicine (R0)